Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas

被引:0
|
作者
Torkildsen, Cecilie Fredvik [1 ,2 ,7 ]
Thomsen, Liv Cecilie Vestrheim [1 ,3 ]
Sande, Ragnar Kvie [2 ,4 ]
Krakstad, Camilla [1 ,3 ]
Stefansson, Ingunn [1 ,5 ]
Lamark, Eva Karin [3 ]
Knappskog, Stian [4 ,6 ]
Bjorge, Line [1 ,3 ]
机构
[1] Univ Bergen, Ctr Canc Biomarkers, Dept Clin Sci, Bergen, Norway
[2] Stavanger Univ Hosp, Dept Obstet & Gynecol, Stavanger, Norway
[3] Haukeland Hosp, Dept Obstet & Gynecol, Bergen, Norway
[4] Univ Bergen, Dept Clin Sci, Bergen, Norway
[5] Haukeland Hosp, Dept Pathol, Bergen, Norway
[6] Haukeland Hosp, Dept Oncol, Bergen, Norway
[7] Univ Bergen, Ctr Canc Biomarkers, Dept Clin Sci, Bergen, Norway
来源
CANCER MEDICINE | 2023年 / 12卷 / 13期
关键词
cancer genetics; clinical observations; gynaecological oncology; mutations; risk model; surgery; RESIDUAL DISEASE; DEBULKING SURGERY; CANCER; SURVIVAL; CHEMOTHERAPY; BEVACIZUMAB; SUBTYPES; SCORE; IMPACT; LEADS;
D O I
10.1002/cam4.6085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundHigh-grade serous ovarian carcinoma (HGSOC) is the deadliest ovarian cancer subtype, and survival relates to initial cytoreductive surgical treatment. The existing tools for surgical outcome prediction remain inadequate for anticipating the outcomes of the complex relationship between tumour biology, clinical phenotypes, co-morbidity and surgical skills. In this genotype-phenotype association study, we combine phenotypic markers with targeted DNA sequencing to discover novel biomarkers to guide the surgical management of primary HGSOC.MethodsPrimary tumour tissue samples (n = 97) and matched blood from a phenotypically well-characterised treatment-naive HGSOC patient cohort were analysed by targeted massive parallel DNA sequencing (next generation sequencing [NGS]) of a panel of 360 cancer-related genes. Association analyses were performed on phenotypic traits related to complete cytoreductive surgery, while logistic regression analysis was applied for the predictive model.ResultsThe positive influence of complete cytoreductive surgery (R0) on overall survival was confirmed (p = 0.003). Before surgery, low volumes of ascitic fluid, lower CA125 levels, higher platelet counts and relatively lower clinical stage at diagnosis were all indicators, alone and combined, for complete cytoreduction (R0). Mutations in either the chromatin remodelling SWI_SNF (p = 0.036) pathway or the histone H3K4 methylation pathway (p = 0.034) correlated with R0. The R0 group also demonstrated higher tumour mutational burden levels (p = 0.028). A predictive model was developed by combining two phenotypes and the mutational status of five genes and one genetic pathway, enabling the prediction of surgical outcomes in 87.6% of the cases in this cohort.ConclusionInclusion of molecular biomarkers adds value to the pre-operative stratification of HGSOC patients. A potential preoperative risk stratification model combining phenotypic traits and single-gene mutational status is suggested, but the set-up needs to be validated in larger cohorts.
引用
收藏
页码:14183 / 14195
页数:13
相关论文
共 50 条
  • [21] Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma
    Bromley, Amy B.
    Altman, Alon D.
    Chu, Pamela
    Nation, Jill G.
    Nelson, Gregg S.
    Ghatage, Praful
    Kalloger, Steve E.
    Han, Guangming
    Koebel, Martin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2012, 31 (05) : 397 - 404
  • [22] The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma
    Gulec, Umran Kucukgoz
    Paydas, Semra
    Guzel, Ahmet Baris
    Vardar, Mehmet Ali
    Khatib, Ghanim
    Gumurdulu, Derya
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2015, 292 (04) : 923 - 929
  • [23] Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer
    Tucker, Susan L.
    Gharpure, Kshipra
    Herbrich, Shelley M.
    Unruh, Anna K.
    Nick, Alpa M.
    Crane, Erin K.
    Coleman, Robert L.
    Guenthoer, Jamie
    Dalton, Heather J.
    Wu, Sherry Y.
    Rupaimoole, Rajesha
    Lopez-Berestein, Gabriel
    Ozpolat, Bulent
    Ivan, Cristina
    Hu, Wei
    Baggerly, Keith A.
    Sood, Anil K.
    CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3280 - 3288
  • [24] Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
    Milanesio, Michela Camilla
    Giordano, Silvia
    Valabrega, Giorgio
    CANCERS, 2020, 12 (05)
  • [25] Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas
    Grimley, Philip M.
    Matsuno, Rayna K.
    Rosenberg, Philip S.
    Henson, Donald E.
    Schwartz, Arnold M.
    Anderson, William F.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (08) : 2256 - 2261
  • [26] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [27] Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss, Esther Louise
    Evans, Tim
    Pearmain, Philippa
    Askew, Sarah
    Singh, Kavita
    Chan, Kiong K.
    Ganesan, Raji
    Hirschowitz, Lynn
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (07) : 1201 - 1207
  • [28] High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women
    Wang, Jingmei
    Wu, Hongyan
    Zhang, Yan
    Zhang, Yifen
    Li, Xinxiu
    Zhao, Qingya
    Meng, Fanqing
    Huang, Qin
    Wang, Yaping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (08): : 8222 - 8232
  • [29] Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
    Talhouk, Aline
    George, Joshy
    Wang, Chen
    Budden, Timothy
    Tan, Tuan Zea
    Chiu, Derek S.
    Kommoss, Stefan
    Leong, Huei San
    Chen, Stephanie
    Intermaggio, Maria P.
    Gilks, Blake
    Nazeran, Tayyebeh M.
    Volchek, Mila
    Elatre, Wafaa
    Bentley, Rex C.
    Senz, Janine
    Lum, Amy
    Chow, Veronica
    Sudderuddin, Hanwei
    Mackenzie, Robertson
    Leong, Samuel C. Y.
    Liu, Geyi
    Johnson, Dustin
    Chen, Billy
    Alsop, Jennifer
    Banerjee, Susana N.
    Behrens, Sabine
    Bodelon, Clara
    Brand, Alison H.
    Brinton, Louise
    Carney, Michael E.
    Chiew, Yoke-Eng
    Cushing-Haugen, Kara L.
    Cybulski, Cezary
    Ennis, Darren
    Fereday, Sian
    Fortner, Renee T.
    Garcia-Donas, Jesus
    Gentry-Maharaj, Aleksandra
    Glasspool, Rosalind
    Goranova, Teodora
    Greene, Casey S.
    Haluska, Paul
    Harris, Holly R.
    Hendley, Joy
    Hernandez, Brenda Y.
    Herpel, Esther
    Jimenez-Linan, Mercedes
    Karpinskyj, Chloe
    Kaufmann, Scott H.
    CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5411 - 5423
  • [30] Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas A Clinicopathologic and Molecular Genetic Analysis
    Ayhan, Ayse
    Kurman, Robert J.
    Yemelyanova, Anna
    Vang, Russell
    Logani, Sanjay
    Seidman, Jeffrey D.
    Shih, Ie-Ming
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (08) : 1220 - 1224